Navigation Links
Osteotech Signs Agreement To Distribute Harvest Technologies' BMAC(TM) System
Date:3/4/2008

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has entered into a three-year agreement with Harvest Technologies Corporation to distribute the BMAC(TM) (Bone Marrow Aspirate Concentrate) System. Under the agreement, Osteotech has the exclusive right to distribute the BMAC(TM) System for bone regeneration in orthopedic and spinal surgical procedures in most of the United States.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "Osteotech is very excited to partner with Harvest for the distribution of the BMAC(TM) System. We believe Harvest's proprietary BMAC(TM) System will complement Osteotech's proprietary technologies in Biocomposite, which includes the Plexur P(TM) and Plexur M(TM), and DBM, furthering Osteotech's regenerative healing equation - Matrix + Signal + Cell."

Mr. Owusu-Akyaw concluded, "We expect to begin to distribute the BMAC(TM) System before the end of the second quarter of 2008. We are currently putting the finishing touches on our roll-out plan and will begin training our sales team shortly. In conjunction with Harvest, we will introduce the BMAC(TM) System at the American Academy of Orthopedic Surgeons 2008 Annual Meeting, March 5 through 7, 2008, in San Francisco, California."

The BMAC(TM) System, developed and manufactured by Harvest, is the first "point-of-care" platform that makes possible the use of a clinically significant quantity of cellular compositions from a small aspirate of bone marrow. The BMAC(TM) System derives bone marrow aspirate concentrate, which is a rich source of autologous adult stem cells, in just 15 minutes.

Harvest, a privately held company based in Plymouth, Massachusetts, has a rich tradition of innovative technologies that are designed to process and concentrate autologous cells and proteins. The BMAC(TM) System incorporates a proprietary floating shelf technology which provides the highest mononuclear cell yield with enhanced viability, osteogenicity and angiogenesis in both animal and in-vitro testing.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of March 4, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
2. Osteotech Completes Tissue Supply Agreement With LifeNet Health
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
5. Pot bellies linked to early signs of cardiovascular disease
6. MSU engineering team designs innovative medical device
7. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
8. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
9. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
10. A new technology for cancer screening listens for the signs of cancer
11. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: